{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:24:10Z","timestamp":1788387850413,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019531","name":"Apellis Pharmaceuticals","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s12325-023-02653-4","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:50:11Z","timestamp":1694699411000},"page":"5115-5129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4871-2114","authenticated-orcid":false,"given":"Vivek","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Koprivnikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Bachelor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"2653_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/ejh.13166","volume":"101","author":"T Devos","year":"2018","unstructured":"Devos T, et al. Diagnosis and management of PNH: review and recommendations from a Belgian expert panel. Eur J Haematol. 2018;101:737\u201349. https:\/\/doi.org\/10.1111\/ejh.13166.","journal-title":"Eur J Haematol"},{"key":"2653_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00277-021-04715-5","volume":"101","author":"D Dingli","year":"2022","unstructured":"Dingli D, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101:251\u201363. https:\/\/doi.org\/10.1007\/s00277-021-04715-5.","journal-title":"Ann Hematol"},{"key":"2653_CR3","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233\u201343. https:\/\/doi.org\/10.1056\/NEJMoa061648.","journal-title":"N Engl J Med"},{"key":"2653_CR4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133:540\u20139. https:\/\/doi.org\/10.1182\/blood-2018-09-876805.","journal-title":"Blood"},{"key":"2653_CR5","unstructured":"Pegcetacoplan. Package insert. Apellis Pharmaceuticals; 2023."},{"key":"2653_CR6","unstructured":"Pegcetacoplan. Summary of product characteristics. Swedish Orphan Biovitrum AB; 2022."},{"key":"2653_CR7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384:1028\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2029073.","journal-title":"N Engl J Med"},{"key":"2653_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12781","volume":"6","author":"S Shah","year":"2022","unstructured":"Shah S, et al. Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: a systematic review on efficacy and safety. Res Pract Thromb Haemost. 2022;6: e12781. https:\/\/doi.org\/10.1002\/rth2.12781.","journal-title":"Res Pract Thromb Haemost"},{"key":"2653_CR9","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2352-3026(22)00210-1","volume":"9","author":"RP de Latour","year":"2022","unstructured":"de Latour RP, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022;9:e648\u201359. https:\/\/doi.org\/10.1016\/S2352-3026(22)00210-1.","journal-title":"Lancet Haematol"},{"key":"2653_CR10","unstructured":"Patriquin CJ, et al. Long-term safety and efficacy of pegcetacoplan treatment in adults with paroxysmal nocturnal hemoglobinuria. American Society of Hematology 64th Annual Meeting and Exposition (New Orleans, LA, USA, 2022)."},{"key":"2653_CR11","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","volume":"10","author":"AM Risitano","year":"2019","unstructured":"Risitano AM, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157. https:\/\/doi.org\/10.3389\/fimmu.2019.01157.","journal-title":"Front Immunol"},{"key":"2653_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bcp.12961","volume":"82","author":"L van Meer","year":"2016","unstructured":"van Meer L, et al. Injection site reactions after subcutaneous oligonucleotide therapy. Br J Clin Pharmacol. 2016;82:340\u201351. https:\/\/doi.org\/10.1111\/bcp.12961.","journal-title":"Br J Clin Pharmacol"},{"key":"2653_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12817","volume":"32","author":"E Thomaidou","year":"2019","unstructured":"Thomaidou E, Ramot Y. Injection site reactions with the use of biological agents. Dermatol Ther. 2019;32: e12817. https:\/\/doi.org\/10.1111\/dth.12817.","journal-title":"Dermatol Ther"},{"key":"2653_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02339-3","author":"MN Yenerel","year":"2022","unstructured":"Yenerel MN, et al. Phase 3 study of subcutaneous versus intravenous ravulizumab in eculizumab-experienced adult patients with PNH: primary analysis and 1-year follow-up. Adv Ther. 2022. https:\/\/doi.org\/10.1007\/s12325-022-02339-3.","journal-title":"Adv Ther"},{"key":"2653_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","volume":"7","author":"A St Clair-Jones","year":"2020","unstructured":"St Clair-Jones A, et al. Understanding and minimising injection-site pain following subcutaneous administration of biologics a narrative review. Rheumatol Ther. 2020;7:741\u201357. https:\/\/doi.org\/10.1007\/s40744-020-00245-0.","journal-title":"Rheumatol Ther"},{"issue":"132","key":"2653_CR16","doi-asserted-by":"publisher","first-page":"16271","DOI":"10.20452\/pamw.16271","volume":"29","author":"U Szlendak","year":"2022","unstructured":"Szlendak U, et al. Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment. Pol Arch Intern Med. 2022;29(132):16271. https:\/\/doi.org\/10.20452\/pamw.16271.","journal-title":"Pol Arch Intern Med"},{"key":"2653_CR17","unstructured":"United Health Group. Just plain clear glossary. Accessed March 9, 2023, https:\/\/www.justplainclear.com"},{"key":"2653_CR18","unstructured":"Centers for Disease Control and Prevention\u2019s National Center for Health Marketing. Plain language thesaurus for health communications (version 10). https:\/\/www.plainlanguage.gov\/media\/Thesaurus_V-10.doc. Accessed March 9, 2023."},{"key":"2653_CR19","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1182\/bloodadvances.2022009129","volume":"7","author":"RSM Wong","year":"2023","unstructured":"Wong RSM, et al. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2023;7:2468\u201378. https:\/\/doi.org\/10.1182\/bloodadvances.2022009129.","journal-title":"Blood Adv"},{"key":"2653_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.5152\/tjh.2011.58","volume":"28","author":"H Goker","year":"2011","unstructured":"Goker H, et al. Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuria. Turk J Haematol. 2011;28:223\u20137. https:\/\/doi.org\/10.5152\/tjh.2011.58.","journal-title":"Turk J Haematol"},{"key":"2653_CR21","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1007\/s12325-023-02510-4","volume":"40","author":"I Bodo","year":"2023","unstructured":"Bodo I, et al. Complement inhibition in paroxysmal nocturnal hemoglobinuria (PNH): a systematic review and expert opinion from central Europe on special patient populations. Adv Ther. 2023;40:2752\u201372. https:\/\/doi.org\/10.1007\/s12325-023-02510-4.","journal-title":"Adv Ther"},{"key":"2653_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62\u201373. https:\/\/doi.org\/10.1111\/bjh.12347.","journal-title":"Br J Haematol"},{"key":"2653_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/ejh.13783","volume":"109","author":"AG Kulasekararaj","year":"2022","unstructured":"Kulasekararaj AG, et al. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. Eur J Haematol. 2022;109:205\u201314. https:\/\/doi.org\/10.1111\/ejh.13783.","journal-title":"Eur J Haematol"},{"key":"2653_CR24","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00277-022-04887-8","volume":"101","author":"D Cella","year":"2022","unstructured":"Cella D, et al. Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study. Ann Hematol. 2022;101:1905\u201314. https:\/\/doi.org\/10.1007\/s00277-022-04887-8.","journal-title":"Ann Hematol"},{"key":"2653_CR25","unstructured":"Ravulizumab-cwvz. Package insert. Alexion Pharmaceuticals, Inc.; 2022."},{"key":"2653_CR26","unstructured":"Ravulizumab-cwvz. Summary of Product Characteristics. Alexion Pharmaceuticals, Inc.; 2023."},{"key":"2653_CR27","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","volume":"36","author":"I Usach","year":"2019","unstructured":"Usach I, et al. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36:2986\u201396. https:\/\/doi.org\/10.1007\/s12325-019-01101-6.","journal-title":"Adv Ther"},{"key":"2653_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ijn.12413","volume":"21","author":"J Carlson","year":"2015","unstructured":"Carlson J, et al. Rituximab for subcutaneous delivery: clinical management principles from a nursing perspective. Int J Nurs Pract. 2015;21:1\u201313. https:\/\/doi.org\/10.1111\/ijn.12413.","journal-title":"Int J Nurs Pract"},{"key":"2653_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jconrel.2020.02.036","volume":"321","author":"DS Collins","year":"2020","unstructured":"Collins DS, et al. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. J Control Release. 2020;321:475\u201382. https:\/\/doi.org\/10.1016\/j.jconrel.2020.02.036.","journal-title":"J Control Release"},{"key":"2653_CR30","unstructured":"Shahin, H, et al. Human factors validation study for a wearable, single-use injector. 48th Annual Oncology Nursing Society Congress (San Antonio, TX, USA, 2023)."},{"key":"2653_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.clinthera.2019.11.015","volume":"42","author":"A Portron","year":"2020","unstructured":"Portron A, et al. A phase I study to assess the effect of speed of injection on pain, tolerability, and pharmacokinetics after high-volume subcutaneous administration of gantenerumab in healthy volunteers. Clin Ther. 2020;42:108-120.e101. https:\/\/doi.org\/10.1016\/j.clinthera.2019.11.015.","journal-title":"Clin Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02653-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02653-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02653-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T10:39:31Z","timestamp":1697020771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02653-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2653"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02653-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"6 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KD, JS, and AB are employees of Apellis Pharmaceuticals, Inc and hold stock options. VS is on the speaker\u2019s bureau for Alexion, Sanofi, and Novo Nordisk. JK: is on the advisory board\/consultant for Apellis, Novartis and Alexion, and is on the speaker's bureau for Alexion, Apellis, Amgen, Jazz, CTI, BMS, and AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The studies included in this analysis were conducted in accordance with Good Clinical Practice and the Declaration of Helsinki [, ]. The study protocols were approved by relevant institutional review boards or ethics committees at each site, and all patients provided written informed consent. PEGASUS and the 307 OLE were registered on ClinicalTrials.gov (NCT03500549 and NCT03531255, respectively).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}